^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab

Published date:
06/23/2021
Excerpt:
...successfully established a 5-genomic mutation signature that included CREBBP, KEAP1, RAF1, STK11 and TP53 mutations....The 5-genomic mutation signature could predict OS benefit for patients with NSCLC receiving atezolizumab.
DOI:
doi.org/10.3389/fimmu.2021.606027